Apellis Pharmaceuticals, Inc. (APLS)

44.19 -3.65 (-7.63%) At close: 04:00PM EDT

Apellis Pharmaceuticals, Inc.

100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700
https://www.apellis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 702

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Cedric Francois M.D., Ph.D.	Co-Founder, President, CEO & Director	1.44M	35.28M	1972
Mr. Mark Jeffrey Delong	Chief Business & Strategy Officer	N/A	N/A	1977
Dr. Philip Ferrone M.D.	Chief Medical Retina Advisor	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Corporate governance

Apellis Pharmaceuticals, Inc.’s ISS governance QualityScore as of 29 April 2024 is 5. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.